Lanifibranor is a Small Molecule owned by Inventiva, and is involved in 9 clinical trials, of which 6 were completed, and 3 are ongoing.

Lanifibranor acts as a agonist of PPAR-alpha, PPAR-gamma and PPAR -delta receptors. The receptors are over expressed in the fibotic tissue. Activation of colonic PPAR gamma activates kinases and transcription factors. These factors include nuclear factor–kappa B, c-Jun, c-Fos and nuclear factor of activated T cell. PPAR gamma activation also inhibits mucosal production of inflammatory cytokines (interleukin-1beta and TNFalpha) and chemokines.

The revenue for Lanifibranor is expected to reach a total of $5.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Lanifibranor NPV Report.

Lanifibranor is originated and owned by Inventiva.

Lanifibranor Overview

Lanifibranor is under development for the treatment of non alcoholic fatty liver disease (NAFLD), type 2 diabetes, liver fibrosis, non-alcoholic steatohepatitis. It is administered through oral route in the form of tablet. It is a new chemical entity. The drug candidate targets (PPAR) peroxisome proliferator-activated receptors (PPAR-alpha, PPAR-gamma and PPAR -delta receptors). It is under development for type 2 diabetes. It was also under development for the treatment of diabetes and systemic sclerosis. It was also under development for the treatment of idiopathic pulmonary fibrosis.

Inventiva Overview

Inventiva is a biopharmaceutical company The company discovers and develops therapies for fibrosis, oncology and lysosomal storage disorders. It’s pipeline products include lanifibranor for non-alcoholic steatohepatitis, odiparcil for mucopolysaccharidosis, ABBV-157 for moderate to severe psoriasis, hippo for non-small cell lung Cancer and mesothelioma, and GEV for idiopathic pulmonary fibrosis. It develops compounds that target nuclear receptors, transcription factors and epigenetic modulation. The company has two innovative clinical programs that are NATIVE and IMPROVES. It conducts its drug discovery research and development in partnership with various medical organizations such as AbbVie, Abbott, Solvay, Fournier. Inventiva is headquartered in Daix, France.

The company reported revenues of (Euro) EUR4.2 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of EUR0.4 million in FY2020. The operating loss of the company was EUR52.1 million in FY2021, compared to an operating loss of EUR29.7 million in FY2020. The net loss of the company was EUR49.6 million in FY2021, compared to a net loss of EUR33.6 million in FY2020.

Quick View – Lanifibranor

Report Segments
  • Innovator
Drug Name
  • Lanifibranor
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Immunology
  • Metabolic Disorders
  • Respiratory
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.